New drug trial aims to stop debilitating neurological attacks
NCT ID NCT05314010
Summary
This study is testing whether the drug MIL62 can safely prevent relapses in adults with neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease that attacks the nerves. Researchers will measure how long it takes for participants to have their first new attack while on the treatment. The goal is to control the disease and reduce the frequency of these damaging flare-ups.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ethics Committee of Chinese PLA General Hosptial
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.